O’Melveny’s Representation of Venturepharma in PE Deal with CVC Asia Pacific Ltd. Noted in Asia Deal Digest

May 07, 2012 According to a May 3, 2012, report in Asia Deal Digest, Beijing-based drug developer Venturepharma Group has turned to O'Melveny & Myers LLP for counsel on a deal in which private equity firm CVC Asia Pacific Ltd. expects to invest US$105 million in the pharmaceutical company.